MONT-SAINT-GUIBERT, Belgium, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a pioneer in the discovery and development of CAR-T cell therapies, today announced that Patrick Jeanmart, Chief Financial Officer and David Gilham, VP Research and Development of Celyad will present a corporate update at the upcoming Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 27th, 2017 at 2:15 p.m. ET in New York, NY.
A live audio webcast of the presentation will be available on the Investor Relations section of Celyad’s website at www.celyad.com/en/investors, where it will be archived for approximately 90 days.
Celyad is a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T cell based therapies. Celyad utilizes its expertise in cell engineering to target cancer. Celyad’s Natural Killer Receptor based T-Cell (NKR-T) platform has the potential to treat a broad range of solid and hematologic tumors. Its lead oncology candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a single dose escalation Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers including five solid tumors (colorectal, ovarian, bladder, triple-negative breast and pancreatic cancers) and two hematological tumors (acute myeloid leukemia and multiple myeloma). Celyad was founded in 2007 and is based in Mont-Saint-Guibert, Belgium, and Boston, Massachusetts. Celyad’s ordinary shares are listed on the Euronext Brussels and Euronext Paris exchanges, and its American Depository Shares are listed on the NASDAQ Global Market, all under the ticker symbol CYAD.
For more information about Celyad, please visit: www.celyad.com
For more information, please contact:
|For Europe: Consilium Strategic Communications |
Chris Gardner and Chris Welsh - T: +44 (0)20 3709 5700 – firstname.lastname@example.org
|For France: NewCap|
Pierre Laurent and Nicolas Mérigeau - T: + 33(0)1 44 71 94 94 - email@example.com
|For Belgium: Comfi|
Gunther De Backer and Sabine Leclercq - T.: +32 (0)2 290 90 90 – firstname.lastname@example.org
|For the U.S.: Stern Investor Relations|
Will O’Connor and Michael Schaffzin – T.: +1 212.362.1200 – email@example.com